But abstinence is often a large bar comparable to demanding that an antidepressant produce complete remission of despair or that an analgesic totally eliminate suffering. Recognizing this limitation, the FDA encourages developers of opioid2 and stimulant3 use problem medications to discuss with FDA alternative strategies to measure changes in drug https://maps.app.goo.gl/ySf3nrmpAxXCtFGHA